BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Pablo-fernández E, Breen DP, Bouloux PM, Barker RA, Foltynie T, Warner TT. Neuroendocrine abnormalities in Parkinson's disease. J Neurol Neurosurg Psychiatry 2017;88:176-85. [DOI: 10.1136/jnnp-2016-314601] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Kamal RE, Menze E, Albohy A, Ahmed HI, Azab SS. Title: Neuroprotective repositioning and anti-tau effect of carvedilol on rotenone induced neurotoxicity in rats: Insights from an insilico&in vivo anti-Parkinson's disease study. Eur J Pharmacol 2022;:175204. [PMID: 35964655 DOI: 10.1016/j.ejphar.2022.175204] [Reference Citation Analysis]
2 Zhao Y, Tan DC, Peng B, Yang L, Zhang SY, Shi RP, Chong CM, Zhong ZF, Wang SP, Liang QL, Wang YT. Neuroendocrine-Immune Regulatory Network of Eucommia ulmoides Oliver. Molecules 2022;27:3697. [PMID: 35744822 DOI: 10.3390/molecules27123697] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Guglielmi P, Carradori S, D'Agostino I, Campestre C, Petzer JP. An updated patent review on monoamine oxidase (MAO) inhibitors. Expert Opin Ther Pat 2022. [PMID: 35638744 DOI: 10.1080/13543776.2022.2083501] [Reference Citation Analysis]
4 Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease. Expert Opin Ther Targets 2022. [PMID: 35584372 DOI: 10.1080/14728222.2022.2079492] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 James E, Keppler J, L Robertshaw T, Sessa B. N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine. Hum Psychopharmacol 2022;37:e2835. [PMID: 35175662 DOI: 10.1002/hup.2835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Souza APDS, Barros WMA, Silva JML, Silva MRM, Silva ABJ, Fernandes MSS, Santos MERAD, Silva MLD, Carmo TSD, Silva RKP, Silva KGD, Souza SL, Souza VON. Effect of Metabolic Syndrome on Parkinson's Disease: A Systematic Review. Clinics (Sao Paulo) 2021;76:e3379. [PMID: 34909941 DOI: 10.6061/clinics/2021/e3379] [Reference Citation Analysis]
7 Rajasekaran S, Peterson PP, Liu Z, Robinson LC, Witt SN. α-Synuclein inhibits Snx3-retromer retrograde trafficking of the conserved membrane-bound proprotein convertase Kex2 in the secretory pathway of Saccharomyces cerevisiae. Hum Mol Genet 2021:ddab284. [PMID: 34570221 DOI: 10.1093/hmg/ddab284] [Reference Citation Analysis]
8 Vaccari C, Grotto D, Pereira TDV, de Camargo JLV, Lopes LC. GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies. PLoS One 2021;16:e0255726. [PMID: 34383800 DOI: 10.1371/journal.pone.0255726] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 de Pablo-Fernández E, Courtney R, Rockliffe A, Gentleman S, Holton JL, Warner TT. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology. Neuropathol Appl Neurobiol 2021. [PMID: 33969516 DOI: 10.1111/nan.12728] [Reference Citation Analysis]
10 Deischinger C, Dervic E, Kaleta M, Klimek P, Kautzky-willer A. Diabetes Mellitus is Associated with a Higher Relative Risk for Parkinson’s Disease in Women than in Men. JPD 2021;11:793-800. [DOI: 10.3233/jpd-202486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Leclerc M, Dudonné S, Calon F. Can Natural Products Exert Neuroprotection without Crossing the Blood-Brain Barrier? Int J Mol Sci 2021;22:3356. [PMID: 33805947 DOI: 10.3390/ijms22073356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhang Y, Li J, Zhang X, Song D, Tian T. Advances of Mechanisms-Related Metabolomics in Parkinson's Disease. Front Neurosci 2021;15:614251. [PMID: 33613180 DOI: 10.3389/fnins.2021.614251] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Fifel K, Videnovic A. Circadian and Sleep Dysfunctions in Neurodegenerative Disorders-An Update. Front Neurosci 2020;14:627330. [PMID: 33536872 DOI: 10.3389/fnins.2020.627330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
14 Vaidya B, Dhamija K, Guru P, Sharma SS. Parkinson's disease in women: Mechanisms underlying sex differences. Eur J Pharmacol 2021;895:173862. [PMID: 33450279 DOI: 10.1016/j.ejphar.2021.173862] [Reference Citation Analysis]
15 Kelly RR, Sidles SJ, LaRue AC. Effects of Neurological Disorders on Bone Health. Front Psychol 2020;11:612366. [PMID: 33424724 DOI: 10.3389/fpsyg.2020.612366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
16 Verugina NI, Levin OS, Lyashenko EA. [Neuroendocrine and metabolic impairments in patients with Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:67-73. [PMID: 33205933 DOI: 10.17116/jnevro202012010267] [Reference Citation Analysis]
17 Liu Y, Bai H, Gen S, Zhang H, Wang S, Hua L, Yang X, Zhang S, Li J, Wang Y. Interaction between SNCA gene polymorphisms and T2DM with Parkinson's disease. Acta Neurol Scand 2020;142:443-8. [PMID: 32484913 DOI: 10.1111/ane.13292] [Reference Citation Analysis]
18 Fifel K, Videnovic A. Circadian alterations in patients with neurodegenerative diseases: Neuropathological basis of underlying network mechanisms. Neurobiol Dis 2020;144:105029. [PMID: 32736083 DOI: 10.1016/j.nbd.2020.105029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Aubignat M, Tir M, Krystkowiak P. [Non-motor symptoms of Parkinson's disease from pathophysiology to early diagnosis]. Rev Med Interne 2021;42:251-7. [PMID: 32680717 DOI: 10.1016/j.revmed.2020.06.019] [Reference Citation Analysis]
20 Yong VW, Tan YJ, Ng YD, Choo XY, Sugumaran K, Chinna K, Md Shah MN, Raja Aman RRA, Moy FM, Mohd Ramli N, Grossmann M, Lim SY, Tan AH. Progressive and accelerated weight and body fat loss in Parkinson's disease: A three-year prospective longitudinal study. Parkinsonism Relat Disord 2020;77:28-35. [PMID: 32615497 DOI: 10.1016/j.parkreldis.2020.06.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Thaler A, Shenhar-Tsarfaty S, Shaked Y, Gurevich T, Omer N, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Cedarbaum JM, Orr-Urtreger A, Giladi N, Mirelman A. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease. Sci Rep 2020;10:9329. [PMID: 32518334 DOI: 10.1038/s41598-020-66319-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
22 Daneshvar Kakhaki R, Ostadmohammadi V, Kouchaki E, Aghadavod E, Bahmani F, Tamtaji OR, J Reiter R, Mansournia MA, Asemi Z. Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Clin Neurol Neurosurg 2020;195:105878. [PMID: 32417629 DOI: 10.1016/j.clineuro.2020.105878] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
23 Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, Skene SS, Greig NH, Kapogiannis D, Foltynie T. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. JAMA Neurol 2019;76:420-9. [PMID: 30640362 DOI: 10.1001/jamaneurol.2018.4304] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 38.5] [Reference Citation Analysis]
24 Mulak A. An overview of the neuroendocrine system in Parkinson's disease: what is the impact on diagnosis and treatment? Expert Rev Neurother 2020;20:127-35. [PMID: 31829756 DOI: 10.1080/14737175.2020.1701437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Steinhardt J, Münte TF, Schmid SM, Wilms B, Brüggemann N. A systematic review of body mass gain after deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease. Obes Rev 2020;21:e12955. [PMID: 31823457 DOI: 10.1111/obr.12955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Camargo Maluf F, Feder D, Alves de Siqueira Carvalho A. Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review. Parkinsons Dis 2019;2019:4951379. [PMID: 31871617 DOI: 10.1155/2019/4951379] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
27 Newhouse A, Chemali Z. Neuroendocrine Disturbances in Neurodegenerative Disorders: A Scoping Review. Psychosomatics 2020;61:105-15. [PMID: 31918850 DOI: 10.1016/j.psym.2019.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 König A, Vicente Miranda H, Outeiro TF. Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease. J Parkinsons Dis 2018;8:33-43. [PMID: 29480231 DOI: 10.3233/JPD-171285] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
29 De Pablo-Fernández E, Courtney R, Warner TT, Holton JL. A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. JAMA Neurol 2018;75:1008-12. [PMID: 29710120 DOI: 10.1001/jamaneurol.2018.0640] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
30 Jellinger KA. Animal models of synucleinopathies and how they could impact future drug discovery and delivery efforts. Expert Opinion on Drug Discovery 2019;14:969-82. [DOI: 10.1080/17460441.2019.1638908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. J Neural Transm (Vienna) 2019;126:933-95. [PMID: 31214855 DOI: 10.1007/s00702-019-02028-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
32 Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, Bhidayasiri R, Wu YR, Shang HF, Evans AH, Pal PK, Hattori N, Tan CT, Jeon B, Tan EK, Lang AE. Parkinson's disease in the Western Pacific Region. Lancet Neurol 2019;18:865-79. [PMID: 31175000 DOI: 10.1016/S1474-4422(19)30195-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 13] [Article Influence: 14.3] [Reference Citation Analysis]
33 Fifel K, Videnovic A. Chronotherapies for Parkinson's disease. Prog Neurobiol 2019;174:16-27. [PMID: 30658126 DOI: 10.1016/j.pneurobio.2019.01.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
34 Todo H. Continuous glucose monitoring can disclose glucose fluctuation in advanced Parkinsonian syndromes. Neurol Int 2018;10:7921. [PMID: 30687470 DOI: 10.4081/ni.2018.7921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
35 Tan AH, Hew YC, Lim SY, Ramli NM, Kamaruzzaman SB, Tan MP, Grossmann M, Ang BH, Tan JY, Manap MAAA, Tay TK, Tan SL, New RP, Fadzli F, Yee EJ, Moy FM, Mahadeva S, Lang AE. Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. Parkinsonism Relat Disord 2018;56:58-64. [PMID: 29914840 DOI: 10.1016/j.parkreldis.2018.06.020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 9.3] [Reference Citation Analysis]
36 De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology 2018;91:e139-42. [PMID: 29898968 DOI: 10.1212/WNL.0000000000005771] [Cited by in Crossref: 87] [Cited by in F6Publishing: 98] [Article Influence: 21.8] [Reference Citation Analysis]
37 Valadas JS, Esposito G, Vandekerkhove D, Miskiewicz K, Deaulmerie L, Raitano S, Seibler P, Klein C, Verstreken P. ER Lipid Defects in Neuropeptidergic Neurons Impair Sleep Patterns in Parkinson's Disease. Neuron 2018;98:1155-1169.e6. [PMID: 29887339 DOI: 10.1016/j.neuron.2018.05.022] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
38 Pak K, Shin HK, Kim E, Lee J, Lyoo CH, Son J, Lee MJ. Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease. Parkinsonism & Related Disorders 2018;51:67-72. [DOI: 10.1016/j.parkreldis.2018.02.044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
39 Marques A, Dutheil F, Durand E, Rieu I, Mulliez A, Fantini ML, Boirie Y, Durif F. Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin? Parkinsonism Relat Disord 2018;55:122-7. [PMID: 29866628 DOI: 10.1016/j.parkreldis.2018.05.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
40 Sharma S, Taliyan R. High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats. Behav Brain Res 2018;351:17-23. [PMID: 29842916 DOI: 10.1016/j.bbr.2018.05.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
41 Mantovani S, Smith SS, Gordon R, O'Sullivan JD. An overview of sleep and circadian dysfunction in Parkinson's disease. J Sleep Res 2018;27:e12673. [PMID: 29493044 DOI: 10.1111/jsr.12673] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
42 Carradori S, Ortuso F, Petzer A, Bagetta D, De Monte C, Secci D, De Vita D, Guglielmi P, Zengin G, Aktumsek A, Alcaro S, Petzer JP. Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents. European Journal of Medicinal Chemistry 2018;143:1543-52. [DOI: 10.1016/j.ejmech.2017.10.050] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
43 Xu K, Alnaji N, Zhao J, Bertoni J, Chen L, Bhatti D, Qu M. Comorbid Conditions in Parkinson’s Disease: A Population-Based Study of Statewide Parkinson’s Disease Registry. Neuroepidemiology 2018;50:7-17. [DOI: 10.1159/000484410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
44 De Pablo-Fernandez E, Sierra-Hidalgo F, Benito-León J, Bermejo-Pareja F. Association between Parkinson's disease and diabetes: Data from NEDICES study. Acta Neurol Scand 2017;136:732-6. [PMID: 28653373 DOI: 10.1111/ane.12793] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
45 Muller S, Brun S, René F, de Sèze J, Loeffler J, Jeltsch-david H. Autophagy in neuroinflammatory diseases. Autoimmunity Reviews 2017;16:856-74. [DOI: 10.1016/j.autrev.2017.05.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
46 Wilczyński J, Pedrycz A, Mucha D, Ambroży T, Mucha D. Body Posture, Postural Stability, and Metabolic Age in Patients with Parkinson's Disease. Biomed Res Int 2017;2017:3975417. [PMID: 28740852 DOI: 10.1155/2017/3975417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
47 Shen Y, Guo X, Han C, Wan F, Ma K, Guo S, Wang L, Xia Y, Liu L, Lin Z, Huang J, Xiong N, Wang T. The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease. Cell Mol Life Sci 2017;74:3741-68. [PMID: 28623510 DOI: 10.1007/s00018-017-2549-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
48 Noyce AJ, Kia DA, Hemani G, Nicolas A, Price TR, De Pablo-Fernandez E, Haycock PC, Lewis PA, Foltynie T, Davey Smith G, Schrag A, Lees AJ, Hardy J, Singleton A, Nalls MA, Pearce N, Lawlor DA, Wood NW; International Parkinson Disease Genomics Consortium. Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. PLoS Med 2017;14:e1002314. [PMID: 28609445 DOI: 10.1371/journal.pmed.1002314] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 17.4] [Reference Citation Analysis]
49 Taghizadeh M, Tamtaji OR, Dadgostar E, Daneshvar Kakhaki R, Bahmani F, Abolhassani J, Aarabi MH, Kouchaki E, Memarzadeh MR, Asemi Z. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Neurochem Int 2017;108:183-9. [PMID: 28342967 DOI: 10.1016/j.neuint.2017.03.014] [Cited by in Crossref: 42] [Cited by in F6Publishing: 56] [Article Influence: 8.4] [Reference Citation Analysis]